A new medical study is happening in Aberdeen to help people with a serious type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). The trial is called TIGOS (or CA245-0001) and is run by a company called Bristol Myers Squibb. The trial is happening in many countries, including the UK . Our cancer research team recruited the first patient in the UK to this study. This is a big success for our team.
What is the study about?
This study is testing a new treatment to see if it works better than the current standard of care. The new medicine is a combination of two drugs: a special antibody that targets cancer cells and a drug that helps the immune system fight cancer. The current standard treatment is a drug called atezolizumab along with chemotherapy. Patients who join the trial will get either the new medicine or the standard treatment.
This trial is important because it could lead to better treatments for lung cancer in the future. We are very grateful to the patient who made the informed decision to join the study.
More information about the study can be found here:
Study Details | NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | ClinicalTrials.gov